Neuberger Berman Group LLC Coherus Bio Sciences, Inc. Transaction History
Neuberger Berman Group LLC
- $130 Billion
- Q3 2025
A detailed history of Neuberger Berman Group LLC transactions in Coherus Bio Sciences, Inc. stock. As of the latest transaction made, Neuberger Berman Group LLC holds 17,108 shares of CHRS stock, worth $20,358. This represents 0.0% of its overall portfolio holdings.
Number of Shares
17,108
Previous 22,371
23.53%
Holding current value
$20,358
Previous $16,000
75.0%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding CHRS
# of Institutions
125Shares Held
54.7MCall Options Held
291KPut Options Held
120K-
Black Rock Inc. New York, NY11.8MShares$14 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.3MShares$12.3 Million0.0% of portfolio
-
Tang Capital Management LLC San Diego, CA5.1MShares$6.07 Million0.38% of portfolio
-
Kohlberg Kravis Roberts & Co. L.P. New York, NY3.04MShares$3.61 Million0.2% of portfolio
-
Geode Capital Management, LLC Boston, MA2.74MShares$3.26 Million0.0% of portfolio
About Coherus BioSciences, Inc.
- Ticker CHRS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 77,724,600
- Market Cap $92.5M
- Description
- Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...